Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

Purpose: Fibroblast growth factor receptor 1 (FGFR1) and FGFR2 amplifications are observed in approximately 10% of breast cancers and are related to poor outcomes. We evaluated whether dovitinib (TKI258), an inhibitor of FGFR1, FGFR2, and FGFR3, presented antitumor activity in FGFR-amplified breast cancers. Experimental Design: Preclinical activity of dovitinib was evaluated in both breast cancer cell lines and an FGFR1-amplified xenograft model (HBCx2). Dovitinib was then evaluated in a phase II trial that included 4 groups of patients with human EGF receptor 2–negative metastatic breast cancer on the basis of FGFR1 amplification and hormone receptor (HR) status. FGFR1 amplification was assessed by silver in situ hybridization. Preplanned retrospective analyses assessed predictive value of FGFR1, FGFR2, and FGF3 amplifications by quantitative PCR (qPCR). Results: Dovitinib monotherapy inhibits proliferation in FGFR1- and FGFR2-amplified, but not FGFR-normal, breast cancer cell lines. Dovitinib also inhibits tumor growth in FGFR1-amplified breast cancer xenografts. Eighty-one patients were enrolled in the trial. Unconfirmed response or stable disease for more than 6 months was observed in 5 (25%) and 1 (3%) patient(s) with FGFR1-amplified/HR-positive and FGFR1-nonamplified/HR-positive breast cancer. When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway–amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway–amplified breast cancer. Conclusion: Dovitinib showed antitumor activity in FGFR-amplified breast cancer cell lines and may have activity in breast cancers with FGF pathway amplification. Clin Cancer Res; 19(13); 3693–702. ©2013 AACR.

[1]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[2]  Philippe Dessen,et al.  Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array , 2009, Clinical Cancer Research.

[3]  J. Kirkwood,et al.  Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma , 2011, Clinical Cancer Research.

[4]  C. Sternberg,et al.  Targeted therapies for renal cell carcinoma: review of adverse event management strategies. , 2012, Journal of the National Cancer Institute.

[5]  P. Goss,et al.  Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Shiuan Chen,et al.  Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer , 2005, Clinical Cancer Research.

[7]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[8]  Hugo M. Horlings,et al.  Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets , 2009, Oncogene.

[9]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[10]  A. Chase,et al.  Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. , 2007, Blood.

[11]  J. Schellens,et al.  The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use , 2011, Clinical Cancer Research.

[12]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[13]  W. Sellers,et al.  FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF‐23 signaling and regulating FGF‐23 expression in bone , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  A. Vincent-Salomon,et al.  A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays , 2007, Clinical Cancer Research.

[15]  Des Powe,et al.  FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis , 2007, Breast Cancer Research.

[16]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[17]  Y. Qi,et al.  Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate , 2010, Breast Cancer Research and Treatment.

[18]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[19]  Peter Kraft,et al.  Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics , 2008, PLoS genetics.

[20]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[21]  M. Mathieu,et al.  FGFR1 and FGF Coamplification in Breast Cancer. , 2009 .

[22]  Alan Mackay,et al.  FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas , 2006, Clinical Cancer Research.

[23]  A. Ashworth,et al.  FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. , 2010, Cancer research.

[24]  Sang Hoon Lee,et al.  In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models , 2005, Clinical Cancer Research.

[25]  J. Baselga,et al.  Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Soria,et al.  TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.